Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013

  Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial
              Results Conference Call on Tuesday, March 19, 2013

PR Newswire

BRIDGEWATER, N.J., Feb. 26, 2013

BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end
2012 financial results will be released prior to the market open on Tuesday,
March 19, 2013. Savient's executive management will host a conference call
beginning at 9:00 a.m. Eastern Time on March 19, 2013, to discuss these
results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or
253-237-1151 (International). The conference ID number is 99134844. The live
and archived webcast can be accessed via the Investor Relations section of the
Savient website at www.savient.com. A telephone replay will be available from
12:00 p.m. Eastern Time on March 19, 2013, through 11:59 p.m. Eastern Time on
March 25, 2013, by dialing 855-859-2056 (Domestic) or 404-537-3406
(International) and entering conference ID number 99134844.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^® (pegloticase) for the treatment
of chronic gout in adult patients who do not respond to conventional therapy.
Savient has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View
Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
U.S. and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. In the U.S., Savient also supplies
Oxandrin^® (oxandrolone tablets, USP) CIII and co-promotes Kineret^®
(anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information,
please visit the Company's website at www.savient.com.

SVNT-I

CONTACT:
Savient Pharmaceuticals, Inc.                     Burns McClellan
John P. Hamill                                    Caitlyn Murphy
Senior Vice President and Chief Financial Officer cmurphy@burnsmc.com
information@savient.com                           (212) 213-0006
(732) 418-9300

SOURCE Savient Pharmaceuticals, Inc.

Website: http://www.savient.com